Prognostic relevance of urinary bladder cancer susceptibility Loci by Grotenhuis, A.J. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/136606
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Prognostic Relevance of Urinary Bladder Cancer
Susceptibility Loci
Anne J. Grotenhuis1, Aleksandra M. Dudek2, Gerald W. Verhaegh2, J. Alfred Witjes2, Katja K. Aben1,3,
Saskia L. van der Marel4, Sita H. Vermeulen1,4, Lambertus A. Kiemeney1,2*
1Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands, 2Department of Urology, Radboud University Medical Center,
Nijmegen, The Netherlands, 3Comprehensive Cancer Center The Netherlands, Utrecht, The Netherlands, 4Department of Human Genetics, Radboud University Medical
Center, Nijmegen, The Netherlands
Abstract
In the last few years, susceptibility loci have been identified for urinary bladder cancer (UBC) through candidate-gene and
genome-wide association studies. Prognostic relevance of most of these loci is yet unknown. In this study, we used data of
the Nijmegen Bladder Cancer Study (NBCS) to perform a comprehensive evaluation of the prognostic relevance of all
confirmed UBC susceptibility loci. Detailed clinical data concerning diagnosis, stage, treatment, and disease course of a
population-based series of 1,602 UBC patients were collected retrospectively based on a medical file survey. Kaplan-Meier
survival analyses and Cox proportional hazard regression were performed, and log-rank tests calculated, to evaluate the
association between 12 confirmed UBC susceptibility variants and recurrence and progression in non-muscle invasive
bladder cancer (NMIBC) patients. Among muscle-invasive or metastatic bladder cancer (MIBC) patients, association of these
variants with overall survival was tested. Subgroup analyses by tumor aggressiveness and smoking status were performed in
NMIBC patients. In the overall NMIBC group (n = 1,269), a statistically significant association between rs9642880 at 8q24 and
risk of progression was observed (GT vs. TT: HR = 1.08 (95% CI: 0.76–1.54), GG vs. TT: HR = 1.81 (95% CI: 1.23–2.66), P for
trend= 2.661023). In subgroup analyses, several other variants showed suggestive, though non-significant, prognostic
relevance for recurrence and progression in NMIBC and survival in MIBC. This study provides suggestive evidence that
genetic loci involved in UBC etiology may influence disease prognosis. Elucidation of the causal variant(s) could further our
understanding of the mechanism of disease, could point to new therapeutic targets, and might aid in improvement of
prognostic tools.
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Introduction
Urinary bladder cancer (UBC) is a heterogeneous disease with
respect to its prognosis. The available prognostic tools that are
based on clinicopathological variables, such as the European
Organisation for Research and Treatment of Cancer (EORTC)
risk tables and the Club Urolo´gico Espan˜ol de Tratamiento
Oncolo´gico (CUETO) scoring model, have insufficient discrimi-
native ability to accurately predict the risk of disease recurrence
and progression at the level of the individual patient. [1] The same
holds for scores that include molecular markers. [2,3] Additional
or better markers are clearly needed for personalized healthcare.
There is growing evidence for a role of (germline) genetic
polymorphisms in disease prognosis and treatment response. [4–
7] Identification of such genetic variants may lead to improvement
of disease outcome prediction in UBC patients. Discovery of such
variants might also provide clues about the underlying mechanism
of urothelial carcinogenesis and cancer progression, and thereby
point the way to new therapeutic targets.
Sufficiently powered and well-designed studies into the prognos-
tic and predictive value of germline genetic polymorphisms in UBC
are rare. Chen et al. identified and (externally) validated the
influence of genetic variation in the sonic hedgehog pathway (i.e.,
rs1233560 in SHH (sonic hedgehog) and rs11685068 in GLI2 (GLI
family zinc finger 2)) on the risk of recurrence after transurethral
resection of the tumor (TURT) in non-muscle invasive bladder
cancer (NMIBC) patients. [8] The same research group discovered
association of a polymorphism in one of the microRNA biogenesis
genes (i.e., rs197412 in DDX20 (DEAD (Asp-Glu-Ala-Asp) box
polypeptide 20)) with disease recurrence in the same UBC
subgroup, which could be replicated in an additional NMIBC
patient series. [9] The remainder of the published candidate-gene
surveys for UBC prognosis is of small size and still awaits
independent replications to exclude false-positive findings. [10–
12] Genome-wide association studies (GWAS) into UBC prognosis
are still lacking. For UBC susceptibility, the shift to an agnostic GWAS
approach has led to the successful identification of several novel,
established genetic polymorphisms. [13] For several cancer types,
including colorectal, pancreatic, breast, lung, and prostate cancer, it
has been shown that GWAS-identified susceptibility variants also
have prognostic relevance. [14–20] Indeed, in one of our GWAS for
UBC susceptibility, we found that the T allele of the identified risk
variant rs798766 (TACC3/FGFR3 (transforming, acidic coiled-coil
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containing protein 3/fibroblast growth factor receptor 3) locus) is
associated with a higher risk of recurrence, specifically among
patients with low-grade Ta tumors. [21] Here, we comprehensively
evaluate the prognostic relevance of 12 variants at 11 (extensively)
replicated UBC susceptibility loci. Our study indicates that there is
overlap in genetic variants underlying UBC etiology and prognosis.
Materials and Methods
Ethics statement
The study was conducted according to the principles expressed
in the declaration of Helsinki. All participants gave written
informed consent and the study was approved by the Institutional
Review Board of the Radboud university medical center,
Nijmegen, the Netherlands.
Patient population
This study was performed in 1,602 patients with primary UBC
from the Nijmegen Bladder Cancer Study (NBCS). The NBCS
served as the Dutch discovery population in the UBC GWAS led
by Radboud university medical center and deCODE Genetics
(Reykjavik, Iceland). The NBCS has been described in detail
before. [13] Patients with a previous or simultaneous (within three
months) diagnosis of upper urinary tract cancer, based on
information from the Netherlands Cancer Registry (NCR), were
excluded. Detailed clinical data concerning diagnosis, stage,
treatment, and disease course (tumor recurrence and progression)
was collected retrospectively by a medical file survey. Based on
stage and histological grade, all NMIBC patients were classified
with regard to tumor aggressiveness (i.e., risk of progression).
Subjects with low risk of progression were defined as those having
TNM stage Ta in combination with WHO 1973 differentiation
grade 1 or 2, WHO/ISUP 2004 low grade, or Malmstro¨m
(modified Bergkvist) grade 1 or 2a. All other patients were
classified as having tumors with high risk of progression (stage CIS
o´r T1 o´r WHO 1973 grade 3, WHO/ISUP 2004 high grade, or
Malmstro¨m (modified Bergkvist) grade 2b or 3). Self-reported data
on smoking status was available based on a lifestyle questionnaire
filled out by the participants at study inclusion.
Selection of variants and genotyping
The ten UBC susceptibility single-nucleotide polymorphisms
(SNPs) that were identified through GWAS for UBC risk and
replicated in at least one independent population, were selected for
this study (see Table 1 for details). All of these SNPs were
genotyped via the Illumina HumanCNV370-Duo BeadChip,
except for rs2736098 that was genotyped by a single-SNP
Centaurus (Nanogen) assay. [22] The genome-wide genotyping
of SNPs in the NBCS, and related quality control (QC) procedures
were described in detail before. [13] The concordance rate
between (UBC susceptibility) SNP genotypes measured using the
Illumina platform and those derived from a single-SNP Centaurus
(Nanogen) assay was previously found to be .99.5%. [13,21,23]
In addition, deletion of the glutathione S-transferase mu 1
(GSTM1) gene (null genotype) and a tag SNP for the N-
acetyltransferase 2 (NAT2) slow acetylation phenotype
(rs1495741) [24], both with an established influence on UBC risk
based on (meta-analysis of) candidate-gene studies, were included
in this study (see Table 1). GSTM1 copy number variation (CNV)
status was determined by an Applied Biosystems TaqMan Copy
Number assay (Assay ID: Hs02575461_cn). The NAT2 tagSNP
was genotyped through the Illumina HumanCNV370-Duo
BeadChip.
As we realize that the 10 GWAS-identified genetic variants
evaluated are not necessarily the causal variants, we also evaluated
genetic variants in a 200 kb region centered on each of the
susceptibility SNPs in relation to each of the prognostic endpoints.
For this, we used genome-wide measured and imputed SNP data.
Imputation was performed using the 1000 Genomes low-coverage
pilot haplotypes (released June 2010, 120 chromosomes) and the
HapMap3 haplotypes (released February 2009, 1920 chromo-
somes) as a combined reference panel. [13] We thereby
automatically included the two UBC susceptibility variants (i.e.,
rs2978974 (8q24.3) and rs17863783 (2q37.1)) that were identified
in previously published finemapping efforts. [25,26]
Outcome definition
In the NMIBC subgroup, the association of the 12 variants with
the prognostic endpoints recurrence-free survival (RFS) and
progression-free survival (PFS) was investigated. Date of first
recurrence was defined as date of histological confirmation of a
newly found bladder or prostatic urethra tumor following at least
one tumor-negative follow-up cystoscopy or two surgical resection
sessions for the primary tumor. Date of first progression was defined as
date of first occurrence of grade progression, stage progression,
local and/or distant metastasis, and/or cystectomy for therapy-
resistant (‘uncontrollable’) disease. See Text S1 for a more detailed
description of the prognostic endpoint definitions. NMIBC
patients who were treated with an immediate radical cystectomy
after primary diagnosis were considered not at risk of (intravesical)
recurrence, and therefore excluded from further analyses. In case
of no recurrence/progression, follow-up was censored at the last
date of urological check-up. Only the first 5 years after the primary
NMIBC diagnosis were considered in the analyses in order to
focus on the most clinically relevant period for those prognostic
endpoints, and also in order to reduce the effect of competing risks
(especially for older patients). RFS and PFS were defined as the
time period between date of the initial TURT and date of first
event (recurrence or progression, respectively), date of censoring,
or date of five-year follow-up, whichever came first.
In the subgroup of muscle-invasive ($T2) or metastatic bladder
cancer (MIBC) patients, the association between the 12 variants
and overall survival (OS) was evaluated. For this purpose,
information on vital status was retrieved via the NCR through
record linkage to the nationwide Dutch Municipal Personal
Records Database. If patients were still alive at December 31st,
2011, follow-up was censored at this date. Again, follow-up time
considered was restricted to the first five years after diagnosis. OS
was defined as the time period between date of the initial TURT
and date of death (of all causes), date of censoring, or date of five-
year follow-up, whichever came first.
Statistical analysis
Kaplan-Meier survival and Cox proportional hazard regression
analyses were performed, and log-rank tests calculated, to evaluate
the association between the 12 variants and the above-mentioned
prognostic endpoints. Multivariable Cox regression analysis was
used to adjust the hazard ratio (HR) for the effect of treatment in
NMIBC patients, and for extended/metastasized (i.e., primary
stage T4(b) o´r any T with N+/N$1 and/or M1) versus localized
disease (i.e., primary stage T2-T4a with N0/NX and M0/MX) at
diagnosis in MIBC patients. To evaluate subgroup-specific effects,
a stratified analysis according to tumor aggressiveness of NMIBC
(i.e., low vs. high risk of progression) and smoking status (i.e., never
vs. ever cigarette smoking) was performed.
The association with disease prognosis was evaluated based on a
genotypic model with the homozygous genotype of the most
Bladder Cancer Risk Loci in Relation to Prognosis
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common (major) allele (based on our data) assigned as the
reference category. For GSTM1 we studied the association for
patients with the null genotype compared to patients with at least
one copy of the gene present, and for NAT2 we evaluated the
association of slow acetylators (rs1495741: AA) compared to
intermediate/rapid acetylators (AG/GG). The Bonferroni correc-
tion was applied to adjust the statistical significance threshold for
the 12 tested variants (alpha = 0.05/12 = 461023) (with P-values
derived based on a (two-sided) trend test). At this alpha level and
assuming a risk allele frequency of 0.20, our study had 80% power
to detect a HR greater than 1.35 and 1.89 for recurrence (five-year
risk: 50%), and a minimum HR of 1.57 and 2.36 for progression
(five-year risk: 20%), according to a dominant and recessive mode
of inheritance, respectively (IBM SPSS SamplePower release 3.01).
In addition to the single-SNP analyses, we evaluated the
cumulative prognostic value of the UBC susceptibility variants by
testing association with the genetic risk score, i.e., total sum of the
number of UBC risk alleles (0,1,2) for each SNP among individuals
successfully genotyped for all 12 variants. For NAT2 and GSTM1,
we counted the risk genotype (0,1). Cumulative (additive)
association with RFS and PFS among NMIBC patients was tested
by including this genetic risk score as continuous (independent)
variable in a Cox regression model (with adjustment for treatment
type). Statistical analyses were performed using IBM SPSS
Statistics for Windows 20 (IBM Corp., Armonk, NY, USA).
Association parameters for the imputed SNP variants surround-
ing the GWAS risk SNPs (according to an additive inheritance
model) were obtained by Cox proportional hazards regression
analyses performed with ProbABEL v0.1-3 from the GenABEL
suite of programs. [27] The Cox proportional hazards model
(pacoxph function) implemented in the ProbABEL-package makes
use of the source code of the R package ‘‘survival’’ as implemented
by T. Lumley. Regional association plots were drawn using
LocusZoom software. [28]
Results
Non-muscle invasive bladder cancer (NMIBC)
Among the total study population of 1,602 UBC patients, 1,327
were diagnosed with NMIBC (stages Ta, T1, CIS). Thirty patients
were excluded because they were previously or simultaneously
diagnosed with cancer of the upper urinary tract. In addition, nine
patients were excluded because the recurrence and progression
status could not be validly assessed based on the medical file
review. Finally, we excluded 19 NMIBC patients who had an
immediate radical cystectomy (see Table S1 for patient and tumor
characteristics). The median time between date of the initial
TURT and date of the last urological check-up visit of the
remaining 1,269 NMIBC patients was 5.3 (interquartile range
(IQR): 3.7–8.7) years. Demographic and clinicopathological
characteristics of both the NMIBC and MIBC group are shown
in Table 2.
Association of UBC susceptibility loci with disease
recurrence. Median time at risk for recurrence of the 1,269
included NMIBC patients was 2.9 years. During the first 5 years
after the primary UBC diagnosis, 601 (Kaplan-Meier 5-year risk:
51.3%) NMIBC patients experienced disease recurrence. None of
the 12 genetic variants examined showed a statistically significant
association with RFS at the Bonferroni-adjusted or nominal
significance level (P,0.05) (see Table 3).
Association of UBC susceptibility loci with disease
progression. Median time at risk for progression of the 1,269
NMIBC patients was 4.9 years. 195 NMIBC patients (Kaplan-
Meier 5-year risk: 17.2%) experienced disease progression during
the first five years after the primary UBC diagnosis. One of the 12
genetic variants, i.e. rs9642880 at the MYC (v-myc avian
myelocytomatosis viral oncogene homolog) locus showed a
statistically significant association with the risk of disease
progression (P for trend = 2.661023). The genotype-specific
results suggest a recessive mode of action (GG vs. TT: HR = 1.81
(95% confidence interval (CI): 1.23–2.66)), with no evidence of a
difference in progression risk between GT heterozygotes and TT
homozygotes (see Table 3 and Figure 1). With a stricter
progression definition, i.e., transition from NMIBC (Ta/T1/CIS)
Table 1. Extensively replicated germline UBC susceptibility loci.
Locus Gene region SNP Risk allelea Allelic ORa
Risk allele
frequencyb Study type Reference
8p22 NAT2 - slow acetylator 1.4 0.56 Candidate-gene [45]
1p13.3 GSTM1 - null 1.5 0.51 Candidate-gene [45]
8q24.21 MYC rs9642880 T 1.22 0.45 GWAS [23]
3q28 TP63 rs710521 A 1.19 0.73 GWAS [23]
5p15.33 TERT rs2736098 A 1.16 0.26 GWAS [22]
5p15.33 CLPTM1L rs401681 C 1.12 0.54 GWAS [22]
8q24.3 PSCA rs2294008 T 1.15 0.46 GWAS [46]
4p16.3 TACC3-FGFR3 rs798766 T 1.24 0.19 GWAS [21]
22q13.1 CBX6, APOBEC3A rs1014971 T 1.14 0.62 GWAS [47]
19q12 CCNE1 rs8102137 C 1.13 0.33 GWAS [47]
2q37.1 UGT1A rs11892031 A 1.19 0.92 GWAS [47]
18q12.3 SLC14A1 rs1058396 G 1.14 0.50 GWAS [13]
OR: odds ratio; TP63: tumor protein p63; TERT: telomerase reverse transcriptase; CLPTM1L: CLPTM1-like; PSCA: prostate stem cell antigen; CBX6: chromobox homolog 6;
APOBEC3A: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A; CCNE1: cyclin E1; SLC14A1: solute carrier family 14 (urea transporter), member 1
afor NAT2 and GSTM1 these do not refer to the risk allele but to the risk genotype;
brisk allele frequency among controls as published in candidate-gene study/GWAS paper
doi:10.1371/journal.pone.0089164.t001
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to muscle-invasive disease ($T2) (60 events within 5 years of
diagnosis; Kaplan-Meier 5-year risk: 5.5%), the association
of rs9642880 became even more pronounced and increased risk
of progression was observed among both heterozygous and
homozygous carriers of the G allele (GT vs TT: HR = 1.49
(95% CI: 0.72–3.08) and GG vs. TT: HR = 3.15 (95% CI: 1.50–
6.61), P for trend= 1.3261023). In addition, the stricter
progression definition revealed nominal evidence for increased
risk of progression among carriers of the rs710521 [G] allele (AG
vs. AA: HR = 1.52 (95% CI: 0.89–2.61) and GG vs. AA: HR =
2.84 (95% CI: 1.24–6.51), P for trend = 0.01) in NMIBC patients.
None of the other risk variants were nominally or statistically
significantly associated with time to progression.
Subgroup analysis according to tumor
aggressiveness. For several of the susceptibility loci, the
etiologic link with bladder cancer was previously reported to be
specific for (or most prominent among) the group with low or high
risk of progression. Therefore, we also evaluated whether the
Table 2. Demographic and clinicopathological characteristics of included NMIBC and MIBC patients
N (%) NMIBC MIBC
N=1,269 N=273
Male gender 1,065 (84) 196 (72)
Median age (range) 64 (25–92) 64 (27–93)
Smoking status Never cigarette smoker 189 (15) 30 (11)
Ever cigarette smoker 887 (70) 165 (60)
Unknown 193 (15) 78 (29)
Tumor stage 0a 866 (68) -
0is 50 (4) -
I 336 (26) -
II - 136 (50)
III - 50 (18)
IV - 87 (32)
Unknown 17 (1.3) -
Tumor grade Low grade 775 (61) 15 (5.5)
High grade 481 (38) 236 (86)
Unknown 13 (1.0) 22 (8.1)
Tumor aggressiveness Low risk of progression 703 (55) -
High risk of progression 552 (44) -
Unknown 14 (1.1) -
Tumor histology UCC 1,257 (99) 240 (88)
SCC - 11 (4.0)
AC 1 (0.1) 9 (3.3)
Other 2 (0.2) 11 (4.0)
Unknown 9 (0.7) 2 (0.7)
Tumor size ,3 cm 181 (14) 15 (5.5)
$3 cm 93 (7.3) 39 (14)
Unknown 995 (78) 219 (80)
Tumor focality Solitary 699 (55) 179 (66)
Multifocal 490 (39) 68 (25)
Unknown 80 (6.3) 26 (9.5)
Initial treatment NMIBC TURT only (6 one immediate p.o. i.v. CT instillation) 552 (44) -
TURT + adjuvant i.v. CT 392 (31) -
TURT + adjuvant i.v. IT 248 (20) -
TURT + both adjuvant i.v. CT and IT 26 (2.1) -
Other 3 (0.2) -
Unknown 48 (3.8) -
Initial treatment MIBCa Curative intent - 186 (68)
Palliative intent - 87 (32)
UCC: urothelial cell carcinoma; SCC: squamous cell carcinoma; AC: adenocarcinoma; p.o.: post-operative; i.v.: intravesical; CT: chemotherapy; IT: immunotherapy
acurative intent corresponds to treatment of tumors of stage T2-T4a with N0/NX and M0/MX; palliative intent corresponds to treatment of tumors of stage T4(b) o´r any T
with N$1/N+ and/or M1
doi:10.1371/journal.pone.0089164.t002
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association with disease recurrence and progression for the 12
genetic variants varies between these NMIBC subgroups. We
adjusted for any remaining treatment variability within the two
NMIBC subgroups. After restriction to NMIBC with known type
of initial treatment, 672 were classified as ‘at low risk of
progression’, and 534 as ‘at high risk of progression’, while for
12 cases aggressiveness could not be determined. Five-year risk of
recurrence is 48% and 52% among low and high risk cases,
respectively (indicating that tumor aggressiveness is not a good
classifier for the risk of recurrence). With respect to progression,
five-year risk varies between 9% among low risk and 26% among
high risk cases. The stratified analysis did not reveal statistically
significant associations in either of the subgroups, not for
recurrence and not for progression; some suggestive findings of
(borderline) nominal significance were found (see Table S2).
Effect modification by smoking status. Because of their
involvement in the detoxification of xenobiotic and carcinogenic
substances (including constituents of cigarette smoke, the main
UBC risk factor), we also evaluated the association of NAT2
acetylation status, GSTM1 CNV, and of the rs11892031 SNP (in
the UDP glucuronosyltransferase 1 family, polypeptide A complex
locus (UGT1A) cluster) with NMIBC prognosis according to
Table 3. Association of confirmed UBC susceptibility variants with NMIBC recurrence and progression
Disease recurrence (N=1,269)a Disease progression (N=1,269)a
SNP/CNV Genotype N (n events) HR (95% CI) P trend N (n events) HR (95% CI) P trend
rs9642880 TT 355 (180) Ref. 0.98 355 (46) Ref. 2.661023
GT 637 (281) 0.84 (0.70–1.01) 637 (88) 1.08 (0.76–1.54)
GG 269 (135) 1.03 (0.82–1.28) 269 (59) 1.81 (1.23–2.66)
rs710521 AA 732 (357) Ref. 0.23 732 (107) Ref. 0.25
AG 468 (212) 0.88 (0.75–1.05) 468 (74) 1.09 (0.81–1.46)
GG 68 (31) 0.94 (0.65–1.36) 68 (14) 1.42 (0.82–2.49)
rs2294008b CC 323 (144) Ref. 0.16 323 (50) Ref. 0.97
CT 699 (332) 1.09 (0.90–1.33) 699 (107) 0.97 (0.69–1.36)
TT 246 (125) 1.19 (0.94–1.51) 246 (38) 1.00 (0.65–1.52)
rs798766 CC 747 (339) Ref. 0.12 747 (118) Ref. 0.40
CT 452 (229) 1.17 (0.99–1.39) 452 (69) 0.96 (0.71–1.29)
TT 69 (33) 1.10 (0.77–1.57) 69 (8) 0.69 (0.34–1.42)
rs401681 CC 436 (212) Ref. 0.76 436 (73) Ref. 0.35
CT 633 (293) 0.89 (0.74–1.06) 633 (94) 0.87 (0.64–1.18)
TT 199 (96) 1.02 (0.80–1.29) 199 (28) 0.84 (0.54–1.30)
rs2736098 GG 482 (211) Ref. 0.36 482 (60) Ref. 0.12
AG 408 (198) 1.12 (0.92–1.36) 408 (64) 1.28 (0.90–1.82)
AA 100 (46) 1.08 (0.78–1.48) 100 (17) 1.39 (0.81–2.39)
rs11892031c AA 1063 (502) Ref. 0.56 1063 (160) Ref. 0.44
AC 201 (95) 1.01 (0.81–1.26) 201 (34) 1.15 (0.79–1.66)
CC 5 (4) 2.43 (0.91–6.50) 5 (1) 1.36 (0.19–9.71)
rs8102137 TT 535 (252) Ref. 0.67 535 (77) Ref. 0.20
CT 580 (273) 0.98 (0.83–1.17) 580 (88) 1.05 (0.77–1.42)
CC 146 (71) 1.10 (0.84–1.43) 146 (28) 1.40 (0.91–2.15)
rs1014971 AA 564 (273) Ref. 0.46 564 (81) Ref. 0.43
AG 585 (274) 0.95 (0.80–1.12) 585 (95) 1.15 (0.86–1.55)
GG 119 (54) 0.92 (0.68–1.23) 119 (19) 1.12 (0.68–1.84)
rs1058396 GG 381 (170) Ref. 0.22 381 (55) Ref. 0.36
AG 625 (296) 1.05 (0.87–1.27) 625 (93) 1.03 (0.74–1.43)
AA 262 (135) 1.16 (0.92–1.45) 262 (47) 1.21 (0.82–1.79)
rs1495741d GG/AG 457 (207) Ref. 0.25 457 (71) Ref. 1.00
AA 811 (394) 1.10 (0.93–1.31) 811 (124) 1.00 (0.75–1.34)
GSTM1 deletion +/+ and +/2 495 (226) Ref. 0.16 495 (87) Ref. 0.08
2/2 680 (327) 1.13 (0.95–1.34) 680 (90) 0.77 (0.57–1.03)
CNV: copy number variant; HR: hazard ratio; CI: confidence interval
aPresented effect estimates and statistical significance are based on univariable Cox proportional hazard regression;
bP for trend for independent rs2978974 SNP at the 8q24.3 locus is 0.75 and 0.83 in relation to NMIBC recurrence and progression, respectively;
cP for trend for causal risk variant (rs17863783) at the 2q37.1 locus is 0.36 and 0.85 in relation to NMIBC recurrence and progression, respectively;
drs1495741: tag SNP for NAT2 acetylation status (GG = rapid, AG = intermediate, AA = slow)
doi:10.1371/journal.pone.0089164.t003
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smoking status (see Table 4). Data on self-reported smoking status
and type of initial treatment was available for 1,035 NMIBC
patients (852 and 183 ever and never (cigarette) smokers,
respectively). The analyses revealed some evidence for an elevated
risk of disease recurrence in NAT2 slow acetylators compared to
patients with an intermediate or rapid acetylation status specifi-
cally among ever smokers (rs1495741 AA vs. AG/GG: HRadj. =
1.29 (1.04–1.61), P for trend = 0.02). Besides, among never
smokers, NAT2 slow acetylation status was found to correlate with
a decreased risk of disease progression compared to intermediate/
rapid acetylators (HRadj. = 0.42 (0.19–0.93), P for trend = 0.03).
No evidence for effect modification by smoking status was found
for the association between GSTM1 CNV or rs11892031 and
NMIBC prognosis.
Interestingly, an exploratory analysis for the other susceptibility
loci indicated association of rs798766 at the 4p16.3 (TACC3-
FGFR3) locus with the risk of disease recurrence specifically among
never smoking NMIBC patients (never cigarette smokers: CT vs.
CC: HRadj. = 2.71 (95% CI: 1.73–4.24) and TT vs. CC: HRadj.
= 2.43 (95% CI: 0.73–8.05), P for trend = 2.761025; ever
cigarette smokers: CT vs. CC: HRadj. = 1.07 (95% CI: 0.86–1.32)
and TT vs. CC: HRadj. = 0.98 (95% CI: 0.63–1.52), P for trend
= 0.75) (see Table 4 and Figure 2).
Prognostic analysis of genetic risk score. In addition to
evaluation of the prognostic relevance of the UBC susceptibility
variants at the single-SNP level, we assessed their cumulative
(additive) effect on NMIBC prognosis by testing association with
the overall number of UBC risk alleles (i.e., the genetic risk score).
After restriction to patients with complete genotype data for all 12
variants and known treatment type, 872 NMIBC patients (390
recurrence and 117 progression events) were included. The
majority of ineligible patients for this analysis were due to a
missing genotype for the rs2736098 SNP (N=279: not included in
Centaurus assay [22]) or the GSTM1 CNV (N=94; insufficient
DNA amount or CNV analysis failed). This analysis indicated a
trend towards a slightly worse RFS (HRadj. = 1.05 (95% CI: 1.00–
1.10, P for trend = 0.05) with each extra risk allele carried. This
translates into a ,1,3-fold and 1,6-fold increased risk of
recurrence among carriers of 5 and 10 risk alleles (compared to
patients with zero UBC risk alleles), respectively. No association
was observed between the genetic risk score and PFS among
NMIBC patients (HRadj. = 0.99 (95% CI: 0.91–1.07), P for trend
= 0.77).
Muscle-invasive and metastatic bladder cancer (MIBC)
The Nijmegen Bladder Cancer Study contains 275 MIBC
patients. Two patients were excluded from the analysis because
they were previously or simultaneously diagnosed with cancer of
the upper urinary tract.
Association of UBC susceptibility loci with overall
survival. Median time at risk for overall death of the 273
MIBC patients was 6.8 (IQR: 3.1–11)) years. During the first 5
years after the primary diagnosis, 81 of the MIBC patients
(Kaplan-Meier 5-year risk: 29.9%) died. None of the 12 variants
evaluated was found to be associated with OS at the Bonferroni-
adjusted statistical significance level (see Table 5). GSTM1 CNV
showed a statistically significant association with OS at the
nominal P,0.05: HR = 1.70 (95% CI: 1.04–2.79) for the patients
with the null genotype versus all others. The association lost
nominal significance however, after adjustment for the survival
difference between patients with extended/metastasized and
localized cancer (see Table 5). Because of the small sample size,
no subgroup analyses were performed.
Regional association analysis
The evaluation of the association of (measured and imputed)
genetic variants within a 200 kb region centered on each of the 10
GWAS-identified susceptibility SNPs did not reveal an association
at the statistical significance threshold P,161024 (on average
,500 variants in 200 kb region) for any of the genetic markers in
Figure 1. Association between rs9642880 (MYC locus) and progression-free survival in NMIBC patients. Kaplan-Meier survival plot
showing association between rs9642880 genotype and progression-free survival (PFS) of non-muscle invasive bladder cancer (NMIBC) patients.
doi:10.1371/journal.pone.0089164.g001
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relation to the endpoints RFS and PFS in the overall NMIBC
subgroup (see Figure S1 and S2) and OS in the MIBC subgroup.
For the MYC locus, rs9642880 shows the second strongest
association signal; rs10094872 shows a slightly stronger association
signal with the risk of NMIBC progression (P= 1.861023; r2
between the two SNPs based on 1000G Pilot 1 CEU data = 0.54).
After adjusting for the effect of rs9642880, the association of
rs10094872 lost strength in terms of the HR and statistical
significance (P= 0.25). The same holds for the association of
rs9642880 (P= 0.37) conditional on the effect of rs10098472,
indicating that both variants represent the same association signal.
Discussion
There is increasing evidence that the same genes or genetic
variants could be implicated in both cancer predisposition, disease
Figure 2. Association between rs798766 (TACC3/FGFR3 locus) and recurrence-free survival in NMIBC patients by smoking status.
Kaplan-Meier survival plots showing association between rs798766 genotype and recurrence-free survival (RFS) in A) never cigarette smokers
(Logrank P = 3.061025) and B) ever cigarette smokers (Logrank P = 0.84) with non-muscle invasive bladder cancer (NMIBC).
doi:10.1371/journal.pone.0089164.g002
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prognosis, and treatment response. So far, this interrelatedness at
the genetic level is particularly observed for genes involved in well-
known oncogenic pathways such as xenobiotic metabolism, DNA
repair, and cell cycle control. [29,30] In addition, several GWAS-
identified cancer susceptibility loci (several with yet unknown
mechanism) have been found to play a role in cancer prognosis.
[14–21] This is the first comprehensive evaluation of the
prognostic relevance of all confirmed UBC susceptibility loci.
Based on this study, for only one of the investigated UBC
susceptibility loci an association with disease prognosis was
identified which passed the multiple testing threshold. This main
finding indicated an effect of the rs9642880 SNP at the MYC locus
on PFS in the overall group of NMIBC patients. Patients with the
rs9642880 GG genotype experienced an increased risk of disease
progression compared to patients with the GT or TT genotype.
Various etiological studies (including the initial GWAS) have
indicated consistently that the risk of UBC is increased for carriers
of the rs9642880[T] allele, which was most pronounced for low
grade Ta tumors. [23,31–35] This etiologic link of rs9642880[T]
with a less aggressive type of UBC could explain the decreased risk
Table 5. Association of confirmed UBC susceptibility variants with overall mortality among MIBC patients.
Unadjusted (N=273) Adjusteda (N=273)
SNP/CNV Genotype N (n events) HR (95% CI) P trend HR (95% CI) P trend
rs9642880 TT 63 (18) Ref. 0.69 Ref. 0.56
GT 139 (39) 0.94 (0.54–1.64) 0.86 (0.49–1.50)
GG 70 (23) 1.12 (0.61–2.08) 1.18 (0.64–2.18)
rs710521 AA 152 (50) Ref. 0.16 Ref. 0.12
AG 101 (27) 0.77 (0.48–1.23) 0.88 (0.55–1.41)
GG 20 (4) 0.59 (0.21–1.63) 0.52 (0.19–1.45)
rs2294008b CC 79 (18) Ref. 0.22 Ref. 0.25
CT 133 (43) 1.45 (0.84–2.52) 1.22 (0.70–2.13)
TT 61 (20) 1.48 (0.78–2.79) 1.45 (0.77–2.74)
rs798766 CC 178 (49) Ref. 0.21 Ref. 0.28
CT 85 (27) 1.13 (0.71–1.80) 1.03 (0.65–1.65)
TT 10 (5) 2.14 (0.85–5.37) 2.41 (0.96–6.05)
rs401681 CC 100 (24) Ref. 0.13 Ref. 0.29
CT 114 (36) 1.29 (0.77–2.17) 1.23 (0.73–2.06)
TT 59 (21) 1.56 (0.87–2.79) 1.39 (0.76–2.45)
rs2736098 GG 99 (31) Ref. 0.10 Ref. 0.35
AG 80 (15) 0.54 (0.29–0.99) 0.64 (0.34–1.19)
AA 18 (4) 0.68 (0.24–1.93) 0.95 (0.33–2.72)
rs11892031c AA 243 (69) Ref. 0.20 Ref. 0.20
AC 30 (12) 1.50 (0.81–2.76) 1.49 (0.81–2.75)
CC 0 (0) NA NA
rs8102137 TT 107 (34) Ref. 0.49 Ref. 0.57
CT 130 (38) 0.92 (0.58–1.45) 0.93 (0.59–1.48)
CC 36 (9) 0.77 (0.37–1.61) 0.81 (0.39–1.69)
rs1014971 AA 123 (34) Ref. 0.97 Ref. 0.92
AG 124 (41) 1.20 (0.76–1.89) 1.05 (0.66–1.66)
GG 26 (6) 0.79 (0.33–1.89) 0.87 (0.37–2.08)
rs1058396 GG 78 (28) Ref. 0.29 Ref. 0.45
AG 137 (37) 0.73 (0.44–1.19) 0.69 (0.42–1.13)
AA 58 (16) 0.75 (0.41–1.39) 0.85 (0.46–1.57)
rs1495741d GG/AG 92 (32) Ref. 0.17 Ref. 0.09
AA 181 (49) 0.73 (0.47–1.14) 0.68 (0.43–1.06)
GSTM1 deletion +/+ and +/2 104 (23) Ref. 0.03 Ref. 0.09
2/2 146 (51) 1.70 (1.04–2.79) 1.53 (0.93–2.51)
CNV: copy number variant; HR: hazard ratio; CI: confidence interval;
awith adjustment for extended/metastasized (i.e., primary stage T4(b) o´r any T with N+/N$1 and/or M1) vs. localized disease (i.e., primary stage T2-T4a with N0/NX and
M0/MX) in multivariable Cox proportional hazard regression analyses;
bP for trend (unadjusted) for independent rs2978974 SNP at the 8q24.3 locus is 0.16;
cP for trend (unadjusted) for causal risk variant (rs17863783) at the 2q37.1 locus is 0.92;
drs1495741: tag SNP for NAT2 acetylation status (GG = rapid, AG = intermediate, AA = slow)
doi:10.1371/journal.pone.0089164.t005
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of progression in carriers of this allele. However, we do observe the
decreased risk of progression in both the low and high risk of
progression subgroups. This implies that within these risk strata
rs9642880[T] confers an additional beneficial influence on the
clinical disease course. Studies in other cancer types show an
association for other (independent) SNPs in the 8q24 chromo-
somal region with disease aggressiveness and/or clinical outcome.
[14,36–41] This strengthens the importance of unraveling the
mystery of this 8q24 locus, a so-called gene desert, which seems to
be involved in the susceptibility and clinical disease course of
multiple cancer types. In addition to validation in an independent
patient population, it requires further investigation whether the
association that we found is mediated through a long-range,
regulatory effect on the 30 kb upstream located MYC proto-
oncogene, or through another biological mechanism. [42,43]
Previously, in one of the publications based on our GWAS for
bladder cancer risk, we described association of the rs798766[T]
allele (TACC3/FGFR3 locus) with an increased risk of disease
recurrence among low-stage low-grade NMIBC cases. [21] We do
observe a similar trend in this paper (low risk of progression
subgroup: CT vs. CC: HRadj. = 1.27 (95% CI: 1.00–1.61), and
TT vs. CC: HRadj. = 1.18 (95% CI: 0.71–1.94), P for trend =
0.09). However the association is less pronounced and does not
pass the significance threshold. This difference in effect estimates
may be explained by the fact that this analysis and the previous
GWAS analysis are based on only a partly overlapping patient
series and use a slightly different recurrence definition. Also, in our
current evaluation, we adjusted for the independent effect of
treatment among the strata according to tumor aggressiveness.
Based on an exploratory analysis, we found indications that the
association between rs798766 and NMIBC recurrence might be
mediated by smoking status, but this has to be confirmed by other
studies.
For several other susceptibility loci, our study provides
suggestive evidence for an association with UBC prognosis,
especially in subgroup analyses, which could reflect the different
molecular pathways that play a role in different disease subtypes.
We presented the association results in this paper, but do not
discuss them in further detail here as these findings first require
replication in independent UBC patient series. Evaluation among
the MIBC subgroup is hampered by the relatively small sample
size. Future analyses should be performed in larger patient series
that allow analyses in relevant subgroups with respect to disease
stage and treatment.
Our prognostic evaluation based on a cumulative genetic risk
score suggests that UBC risk loci might collectively influence
NMIBC recurrence. This finding may be due to a cumulative
effect of multiple small increases in recurrence risk conferred by
several of the susceptibility variants.
Where classification of NMIBC patients into two risk strata with
respect to tumor aggressiveness resulted in reasonable discrimina-
tion in the risk of progression in our cohort, it appeared to be a
poor classifier for disease recurrence. Lack of data on tumor size
and exact tumor number (two important recurrence predictors in
the EORTC risk model but characteristics that are poorly
documented in medical charts) for a large proportion of patients
limited us in our possibilities to improve prognostic risk
classification. Risk group stratification according to European
Association of Urology (EAU) guidelines (i.e., low, intermediate,
high risk) resulted in too low event numbers to perform valid
prognostic evaluation. [44] Consequently, the ‘low risk of
progression’ subgroup contains a mix of low and intermediate
risk cases, which could have diminished the power to detect
subgroup-specific associations. However, we adjusted for remain-
ing treatment variability among both risk strata, and thereby
expect to have (indirectly) corrected for the correlated prognostic
variables incorporated in the EORTC scoring system. In contrast
to data underlying the EORTC prediction model, this study
focused on primary bladder cancers (no prior recurrences), which
most likely diminished variability in recurrence risk due to lack of
cases at the higher end of the spectrum.
Major strengths of this study are the population-based nature,
the relatively large sample size, and the medical file review of all
patients. A weakness of the study is the prevalent sampling frame
of part of the study cohort, which might have led to a relatively
healthy study population with possible implications for the
generalizability of our study findings to all UBC patients. We
expect that this selection is negligible in NMIBC patients,
especially with respect to the endpoint recurrence. The relatively
high five-year OS in the MIBC subgroup (,70%) could reflect the
effect of prevalent case sampling. The selection of patients with a
less severe disease course could have resulted in some bias in the
effect size measures.
With exception of our finding for the MYC locus, this study
provides only suggestive evidence that genetic loci involved in
UBC etiology have prognostic relevance. Replication studies in
independent UBC series are necessary to confirm our findings,
and should include evaluation among (disease) subgroups.
Elucidation of the causal mechanism in functional analyses will
further our understanding of the disease, might eventually point
the way to potential new therapeutic targets, and could aid in
further improvement of prognostic risk discrimination.
Note
After acceptance of this research paper, Figueroa et al. [48]
reported on two new GWAS-identified UBC susceptibility loci.
We included the association results of these two UBC risk variants
(i.e., rs10936599 (3q26.2) and rs907611 (11p15.5)) with disease
prognosis in File S1. For both variants, we did not observe
association with clinical outcome that passed the Bonferroni-
adjusted statistical significance threshold, in both the NMIBC and
MIBC subgroup.
Supporting Information
Figure S1 Regional association plots for NMIBC recurrence of
200 kb region centered on 10 GWAS-identified susceptibility
SNPs. A–J) In the above plots, directly genotyped and imputed
single-nucleotide polymorphisms (SNPs) distributed in a 200 kb
region centered on each of the 10 respective GWAS-identified
urinary bladder cancer (UBC) susceptibility SNPs are depicted by
filled circles. For each SNP, the chromosomal location (NCBI
Build 36/hg18) is shown on the x-axis and the significance level for
association with non-muscle invasive bladder cancer (NMIBC)
recurrence is indicated by a -log10 P-value on the left y-axis. In
each plot, the GWAS-identified UBC susceptibility SNP at the
respective locus is represented by a purple diamond. Local linkage
disequilibrium (LD) structure is reflected by the plotted estimated
recombination rates from 1000 Genomes Pilot June 2010 CEU
(light blue line, right y-axis). The level of correlation (LD) of the
UBC susceptibility SNP to other SNPs at the locus (pair wise r2
values) are indicated by a color range from dark blue to red (see
legend). SNPs with missing LD information are shown in grey.
Below the graph, gene annotations are shown as horizontal dark
blue lines. Regional association plots are shown for the A) 2q37.1
locus (rs11892031): most significant association for rs116323695
(P= 2.35E-02), B) 3q28 locus (rs710521): most significant
association for rs3773928 (P= 2.03E-03), C) 4p16.3 locus
Bladder Cancer Risk Loci in Relation to Prognosis
PLOS ONE | www.plosone.org 10 February 2014 | Volume 9 | Issue 2 | e89164
(rs798766): most significant association for rs73081713 (P= 5.09E-
03), D) 5p15.33 locus (rs2736098): most significant association for
rs6420010 (P= 6.55E-03), E) 5p15.33 locus (rs401681): most
significant association for rs116612249 (P= 8.29E-03), F) 8q24.3
locus (rs2294008): most significant association for rs118159558
(P = 2.33E-03), G) 8q24.21 locus (rs9642880): most significant
association for rs80238840 (P= 7.65E-03), H) 18q12.3 locus
(rs1058396): most significant association for rs8088466
(P = 7.72E-03), I) 19q12 locus (rs8102137): most significant
association for rs117125197 (P = 6.16E-02), J) 22q13.1 locus
(rs1014971): most significant association for rs7584 (P= 1.3E-02).
(ZIP)
Figure S2 Regional association plots for NMIBC progression of
200 kb region centered on 10 GWAS-identified susceptibility
SNPs. A–J) In the above plots, directly genotyped and imputed
single-nucleotide polymorphisms (SNPs) distributed in a 200 kb
region centered on each of the 10 respective GWAS-identified
urinary bladder cancer (UBC) susceptibility SNPs are depicted by
filled circles. For each SNP, the chromosomal location (NCBI
Build 36/hg18) is shown on the x-axis and the significance level for
association with non-muscle invasive bladder cancer (NMIBC)
progression is indicated by a -log10 P-value on the left y-axis. In
each plot, the GWAS-identified UBC susceptibility SNP at the
respective locus is represented by a purple diamond. Local linkage
disequilibrium (LD) structure is reflected by the plotted estimated
recombination rates from 1000 Genomes Pilot June 2010 CEU
(light blue line, right y-axis). The level of correlation (LD) of the
UBC susceptibility SNP to other SNPs at the locus (pair wise r2
values) are indicated by a color range from dark blue to red (see
legend). SNPs with missing LD information are shown in grey.
Below the graph, gene annotations are shown as horizontal dark
blue lines. Regional association plots are shown for the A) 2q37.1
locus (rs11892031): most significant association for rs13009407
(P = 3.24E-03), B) 3q28 locus (rs710521): most significant
association for rs76380205 (P= 5.07E-03), C) 4p16.3 locus
(rs798766): most significant association for rs73081713
(P= 9.29E-03), D) 5p15.33 locus (rs2736098): most significant
association for rs246993 (P = 2.49E-03), E) 5p15.33 locus
(rs401681): most significant association for rs246993 (P= 2.49E-
03), F) 8q24.3 locus (rs2294008): most significant association for
rs73716487 (P= 3.26E-04), G) 8q24.21 locus (rs9642880): most
significant association for rs10094872 (P= 1.83E-03), H) 18q12.3
locus (rs1058396): most significant association for rs12454702
(P= 8.85E-03), I) 19q12 locus (rs8102137): most significant
association for rs16963425 (P= 5.46E-02), J) 22q13.1 locus
(rs1014971): most significant association for rs7289061
(P= 2.25E-04).
(ZIP)
File S1 Association of two newly confirmed GWAS-identified
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